Innovo Therapeutics

Executive Summary

Innovo Therapeutics is a private biotechnology company headquartered in Cambridge, Massachusetts, founded in 2017. The company leverages artificial intelligence and machine learning to design and develop novel small molecule therapies, with a primary focus on oncology and inflammatory diseases. By integrating computational drug discovery with experimental validation, Innovo aims to accelerate the identification of high-quality drug candidates and address significant unmet medical needs. While the company is still in early stages with no disclosed pipeline or clinical-stage assets, its AI-driven platform positions it within a competitive landscape that has seen increasing interest from pharmaceutical partners and investors. Innovo’s approach holds promise for improving the efficiency and success rate of drug development, potentially leading to transformative treatments for patients suffering from challenging conditions.

Upcoming Catalysts (preview)

• Q3 2026Series A or Significant Funding Round70% success
• Q4 2026Announcement of Lead Candidate Selection50% success
• Q2 2027Pharmaceutical Partnership or Collaboration40% success